Cancer glossary
Trastuzumab (Herceptin): who gets it, how it is given and heart checks
Trastuzumab is a targeted drug against HER2. Which cancers it treats, how long treatment lasts, how the under-the-skin form differs and why you need echocardiograms.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026
In short
Trastuzumab (original brand Herceptin) is a monoclonal antibody that binds to the HER2 protein on tumor cells and stops them dividing. It only works in HER2-positive tumors.
How it appears in your prescription
- ‘Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks’ — into a vein.
- ‘Trastuzumab 600 mg subcutaneously every 3 weeks’ — the under-the-skin form.
- ‘Trastuzumab + pertuzumab + docetaxel’ — a common regimen in HER2-positive cancer.
What it means
According to the US National Cancer Institute, trastuzumab is approved for HER2-positive breast cancer — before surgery, after it and for metastatic disease — and for HER2-positive stomach cancer. It is usually combined with chemotherapy and, where needed, with pertuzumab. Standard trastuzumab is not used for HER2 0 or HER2-low without amplification; for HER2-low there is a separate drug, trastuzumab deruxtecan.
Side effects
Most common are reactions during the first infusion (chills, fever) and fatigue. The main risk is cardiotoxicity, a drop in how well the heart pumps. That is why an echocardiogram is done before treatment and usually every 3 months during it. Changes are most often reversible if treatment is paused in time.
Tell your doctor about shortness of breath with ordinary activity, swollen legs or a racing heartbeat.
Questions to ask your doctor
- How many infusions in total, and what happens after the last one?
- How often will I have an echocardiogram, and what if my ejection fraction drops?
- Into a vein or under the skin — does it make a difference for me?
Sources
- Trastuzumab — National Cancer Institute
- Targeted Therapy for Breast Cancer — National Cancer Institute
- 2022 ESC Guidelines on cardio-oncology — European Society of Cardiology, 2022
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
